Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07136077
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Sponsor: BeiGene
Conditions
Adjuvant Chemotherapy Colorectal Cancer Fruquintinib Minimal Residual Disease Tislelizumab ctDNA
Interventions
Fruquintinib Tislelizumab
Updated 3 times since 2025 Last updated: Feb 25, 2026 Started: Sep 18, 2025 Primary completion: Apr 1, 2026 Completion: Apr 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Adjuvant Chemotherapy and Colorectal Cancer, this trial is actively recruiting participants. The trial is conducted by BeiGene and has accumulated 3 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
3 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Oct 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- BeiGene
- M.D. Anderson Cancer Center
- Takeda Pharmaceutical Co. Limited
Data source: M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .